Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
23Andme Holding Co.
(NQ:
ME
)
0.5868
-0.0103 (-1.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 23Andme Holding Co.
< Previous
1
2
Next >
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
May 16, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
May 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Releases New Report Revealing Likelihood of Developing Lupus
May 09, 2023
23andMe+ members can now gain insights on the chronic autoimmune condition
From
23andMe Holding Co.
Via
GlobeNewswire
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
May 08, 2023
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
April 14, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
April 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
March 24, 2023
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented
From
23andMe Holding Co.
Via
GlobeNewswire
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
March 09, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and...
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
February 22, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 10, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
TheNewswire.com
23andMe Reports FY2023 Second Quarter Financial Results
November 07, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07, 2022
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
October 27, 2022
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for...
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Report FY2023 Second Quarter Financial Results
October 24, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
October 12, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
October 05, 2022
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Report FY2023 First Quarter Financial Results
July 25, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Florida Credit Firm Leading Credit Repair Firm in all 50 states.
February 25, 2022
5 reasons why we are Rated #1 Credit Repair Firm in the United States. Helping Clients all over the 50 states fixing their credit.
Via
IssueWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.